Unbiased AI-powered news
2 stories related to this topic, newest first.
swissinfo.chA phase III trial for the mRNA-1018 vaccine targeting H5N1 bird flu has begun in the UK and US, involving 4000 volunteers. The trial focuses on immune response strength amid ongoing global spread of the virus in animals. Funded by CEPI, it follows successful earlier phases with n…
Substrate placeholder — needs reviewModerna has received marketing authorization from the European Commission for MCOMBRIAX, its mRNA combination vaccine against influenza and COVID-19. This enables distribution in European markets. The vaccine targets respiratory viruses with combined protection.